All News

Suboptimal adherence with antidementia drugs is associated with poorer clinical outcomes including accelerated disease progression and symptomatology.

ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.

Viking Therapeutics initiates phase 3 trials for VK2735, a promising dual incretin agonist targeting obesity and other metabolic disorders, based on strong phase 2 findings.

Your daily dose of the clinical news you may have missed.

Atopic dermatitis is not just "another rash on the schedule. It could the the reason that patient doesn't leave the house."

In the phase 2b trial, the IL-2 pathway agonist and Treg proliferator demonstrated a strong dose-dependent biological response across 3 treatment arms vs placebo.

The now 7-member ACIP will discuss dated issues including thimerosal in flu vaccine and MMR-related febrile seizures but not vaccines against cervical cancer and pneumonia.

RAD 2025: Multidisciplinary collaboration at disease-specific meetings drives clinical and therapeutic progress in AD, Dr Yu told Patient Care.

Your daily dose of the clinical news you may have missed.

Dermatologists aren't trained in mental health but once in practice they need to have a deep appreciation for the emotional impact of diseases like AD and a low bar for mental health referral.